Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083586 | 0.86 | CYP11B2 (0.55) | TRPV1MEN1KMT2ACYP11B2SMN1; SMN2 | |
| SCHEMBL14083572 | 0.85 | TRPV1 (0.60) | TRPV1CYP11B2GRM4 | |
| SCHEMBL14083600 | 0.85 | TRPV1 (0.53) | TRPV1CSF1RMEN1KMT2ACYP11B2 | |
| SCHEMBL14083535 | 0.84 | TRPV1 (0.62) | TRPV1CSF1RATRBRAFSIRT1 | |
| SCHEMBL14083590 | 0.84 | RAB9A (0.57) | TRPV1CSF1RMEN1KMT2AMAPT | |
| SCHEMBL14083947 | 0.83 | CSF1R (0.49) | TRPV1CSF1RMEN1KMT2AATR | |
| SCHEMBL14083624 | 0.82 | TRPV1 (0.54) | TRPV1CYP11B2GRM4 | |
| SCHEMBL14083581 | 0.82 | CYP11B2 (0.67) | TRPV1CSF1RMEN1KMT2ACYP11B2 | |
| SCHEMBL14083585 | 0.82 | MAPT (0.56) | TRPV1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL14083601 | 0.82 | GRM4 (0.55) | TRPV1MEN1KMT2ACYP11B2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885CSF1R 2217/4885MEN1 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.